The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Mechanisms of Androgen-Refractory Prostate Cancer
Abstract
Prostate cancer is the second-leading cause of cancer-related death among men and the seventh most common cause of death in the United States overall. Most prostate cancers are androgen-dependent, meaning that they respond to androgen-ablation therapy. However, these tumors eventually become androgen-independent and grow despite androgen ablation. When prostate cancer is localized in the prostate, the treatment of choice is prostatectomy or irradiation. However, when the tumor relapses or is already metastatic at diagnosis, therapy is problematic. Androgen ablation has been the main option for unconfined disease for more than 50 years, since Clarence V. Hodges and Charles B. Huggins . . .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Petrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Androgen Receptor Signaling in Androgen-Refractory Prostate Cancer
Grossmann, M. E., Huang, H., & Tindall, D. J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.22.1687 · Cited by 548
Self-citation
Cited by
Rosenfeld, M. G., Lunyak, V. V., & Glass, C. K. (2006) · Genes & Development · doi:10.1101/gad.1424806 · Cited by 952
Yue, S., Li, J., Lee, S.-Y., Lee, H. J., Shao, T., Song, B., Cheng, L., Masterson, T. A., Liu, X., Ratliff, T. L., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.019 · Cited by 929
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 902
Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
Heemers, H. V., & Tindall, D. J. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0019 · Cited by 753
Self-citationWang, Q., Li, W., Liu, X. S., Carroll, J. S., Jänne, O. A., Keeton, E. K., Chinnaiyan, A. M., Pienta, K. J., & Brown, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.041 · Cited by 687
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
Hussain, M., Tangen, C. M., Berry, D. L., Higano, C. S., Crawford, E. D., Liu, G., Wilding, G., Prescott, S., Kanaga Sundaram, S., Small, E. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212299 · Cited by 580
PI3K/Akt/mTOR pathway as a target for cancer therapy
Morgensztern, D., & McLeod, H. L. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000173476.67239.3b · Cited by 468
Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer
Pienta, K. J., & Bradley, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0067 · Cited by 430
Ryan, C. J., Smith, M. R., Fong, L., Rosenberg, J. E., Kantoff, P., Raynaud, F., Martins, V., Lee, G., Kheoh, T., Kim, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1281 · Cited by 396
Moilanen, A.-M., Riikonen, R., Oksala, R., Ravanti, L., Aho, E., Wohlfahrt, G., Nykänen, P. S., Törmäkangas, O. P., Palvimo, J. J., & Kallio, P. J. (2015) · Scientific Reports · doi:10.1038/srep12007 · Cited by 379
Regulation of androgen receptor activity by tyrosine phosphorylation.
Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V. D., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.021 · Cited by 364
van den Eertwegh, A. J., Versluis, J., van den Berg, H. P., Santegoets, S. J., van Moorselaar, R. J. A., van der Sluis, T. M., Gall, H. E., Harding, T. C., Jooss, K., Lowy, I., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70007-4 · Cited by 357
Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
Zhu, M.-L., Horbinski, C. M., Garzotto, M., Qian, D. Z., Beer, T. M., & Kyprianou, N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0585 · Cited by 352
Miller, T. W., Balko, J. M., Fox, E. M., Ghazoui, Z., Dunbier, A., Anderson, H., Dowsett, M., Jiang, A., Smith, R. A., Maira, S.-M., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0101 · Cited by 346
Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing
Fei, T., Chen, Y., Xiao, T., Li, W., Cato, L., Zhang, P., Cotter, M. B., Bowden, M., Lis, R. T., Zhao, S. G., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617467114 · Cited by 338
Soy isoflavones and prostate cancer: A review of molecular mechanisms
Mahmoud, A. M., Yang, W., & Bosland, M. C. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.12.010 · Cited by 281
Androgen‐responsive long noncoding RNA CTBP1‐AS promotes prostate cancer
Takayama, K., Horie‐Inoue, K., Katayama, S., Suzuki, T., Tsutsumi, S., Ikeda, K., Urano, T., Fujimura, T., Takagi, K., Takahashi, S., et al. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.99 · Cited by 278
Zhu, P., Baek, S. H., Bourk, E. M., Ohgi, K. A., Garcia-Bassets, I., Sanjo, H., Akira, S., Kotol, P. F., Glass, C. K., Rosenfeld, M. G., et al. (2006) · Cell · doi:10.1016/j.cell.2005.12.032 · Cited by 259
Androgen Receptor Structural and Functional Elements: Role and Regulation in Prostate Cancer
Dehm, S. M., & Tindall, D. J. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0223 · Cited by 253
Self-citationCastration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets
Chi, K. N., Bjartell, A., Dearnaley, D., Saad, F., Schröder, F. H., Sternberg, C., Tombal, B., & Visakorpi, T. (2009) · European Urology · doi:10.1016/j.eururo.2009.06.027 · Cited by 253
Secondary Hormonal Therapy for Advanced Prostate Cancer
Lam, J. S., Leppert, J. T., Vemulapalli, S. N., Shvarts, O., & Belldegrun, A. S. (2006) · Journal of Urology · doi:10.1016/s0022-5347(05)00034-0 · Cited by 153
Seaton, A., Scullin, P., Maxwell, P. J., Wilson, C., Pettigrew, J., Gallagher, R., O'Sullivan, J. M., Johnston, P. G., & Waugh, D. J. J. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn109 · Cited by 143
Ai, J., Wang, Y., Dar, J. A., Liu, J., Liu, L., Nelson, J. B., & Wang, Z. (2009) · Molecular Endocrinology · doi:10.1210/me.2009-0188 · Cited by 126
Androgen regulation of gene expression.
(2010) · Advances in cancer research · doi:10.1016/s0065-230x(10)07005-3 · Cited by 117
Dehm, S. M., Regan, K. M., Schmidt, L. J., & Tindall, D. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1267 · Cited by 84
Self-citationAndrogen receptor abnormalities in castration-recurrent prostate cancer.
Nacusi, L. P., & Tindall, D. J. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.09.34 · Cited by 27
Self-citation
Metadata
- Authors
- Debes, J. D., & Tindall, D. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-10-07
- Volume
- 351
- Issue
- 15
- Pages
- 1488-1490
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2066086539
- Cited by
- 558
- References
- 5
- FWCI
- 20.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.